Kalorama Information is a dependable resource for information on opportunity in the pharmaceutical market. The pharma industry has seen important developments in the last few years, bringing both challenges and new opportunities. The industry outlook for many manufacturers has changed due to outsourcing in drug discovery, growing generic competition and greater interest in biotechnology, among other developments. Our reports provide the sales data, revenue forecasts, and competitive analysis that one needs to understand the market.
Vaccines
Drug Delivery
Over-the-Counter
Drug Discovery
Cancer Treatment
Manufacturing & Packaging
Prescription Drugs
- Display 45 Products per page
Published: March 27, 2018 | Price: $0.00
This brief White Paper lists over one hundred companies that are involved in drug discovery in one form or another. A company website and address is provided for each company. The White Paper does not detail companies or discuss the CRO marketplace - for this purpose, please consult our recent report, Outsourcing in Drug Discovery, 8th Edition.Published: December 12, 2017 | Price: $2,000.00 – $4,000.00
50 Key Biopharmaceutical and Biotechnology Companies Biopharmaceutical companies bring to market products that hold great promise for treating some of the most intractable medical conditions such as cancer and autoimmune disease. Biotech opportunities largely mirror those in the pharmaceutical industry. The key difference is that biotech firms are much more focused on research because they are still developing their initial products. 50 Key Biopharmaceutical and Biotechnology Companies is a comprehensive look at the top 50 companies that are shaping the...Published: December 1, 2010 | Price: $2,500.00 – $5,000.00
Drug delivery is evolving at a rapid rate with new drug product formulations being discovered frequently. Advanced drug delivery deals with developing solutions for new entities in therapeutic pharmacology such as protein and peptides and other novel compounds targeting drugs to specific disease sites including gene therapy. Treatments for chronic conditions and growth in patient-administered drugs are factors leading to greater focus on ease-of-use and convenience. Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) details the types of drug...Published: July 18, 2003 | Price: $2,625.00 – $5,250.00
Drug delivery technologies continue to be a vital piece of the pharmaceutical marketing puzzle. From clinical efficacy to product differentiation and life-cycle management, delivery technologies are increasingly demanding the attention of developers at earlier and earlier stages. In Kalorama’s 2001-2002 Drug Delivery series, we focused on the markets by route of administration—oral, injectable, implantable, pulmonary, transdermal etc. In this all new study on advanced drug delivery, however, we focused on drug delivery through the lens of therapeutic application. This report...Published: July 1, 2006 | Price: $2,995.00 – $7,800.00
Ophthalmology is entering one of the most remarkable phases in recent history of this industry; new technologies and treatment modalities for both visual acuity and major eye diseases may dramatically change the composition and competitive dynamics of this market. As RK and LASIK changed the market a few years ago, even newer competitive technologies are just now emerging. From the advent of photodynamic therapy and new drug delivery techniques to revolutionary surgical approaches to refractive vision correction, ophthalmology is poised...Published: August 1, 2004 | Price: $895.00 – $1,790.00
After years of neglect, concerns over pain, how it is assessed and managed on a patient-by-patient basis have captured the attention of health care professionals and the public. There are a variety of issues that have acted to draw this attention, including the high prevalence of pain, continuing evidence that pain is undertreated and a growing awareness of the negative consequences of poor pain management. Infusion pumps were first introduced in the 1960s. These devices ushered in a whole new...Published: July 1, 2007 | Price: $2,500.00 – $5,000.00
An understanding of the market for anesthesia could be worthwhile to any pharmaceutical marketer and any equity company investing or consulting in this area. Anesthesia markets are in one sense simple: growth in these drugs are correlated to prevalence and incidence in disease, and the resulting increase in procedure volumes. But as this market continues to grow, increased competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas of the world. New...Published: April 1, 2007 | Price: $2,995.00 – $5,990.00
The market for antibiotics has changed and a knowledge of the current drug resistance situation is critical before operating in this marketplace. The effectiveness of many antibacterials (antibiotics) is being reduced as more and more types of bacteria become resistant to them. These and other developments are covered in Kalorama's Anti-Infectives, World Markets, Vol. II: Antibacterials providing extensive detail on the anti-bacterial market, including the following critical trends: Drug resistance and Interactions Antibiotic Abuse Antibiotic Cycling Addressing Market Trends Antibiotic...Published: May 1, 2007 | Price: $2,700.00 – $5,990.00
This third volume of Kalorama Information’s World Market for Anti-Infectives series, the 2nd. Edition focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides: Revenue Data by Infection Type An overview of products on the market Review of products in the development pipeline Market estimates and forecasts through 2011 Market segmentation by geographic region...Published: March 1, 2007 | Price: $2,500.00 – $5,990.00
Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections. This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been...Published: July 1, 2007 | Price: $5,995.00 – $11,990.00
This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic competition. Antifungals Antibacterials Antivirals As part of its comprehensive coverage, each report includes: Epidemiology including Incidence Statistics for each type of infection. Current Market Size and Revenue Forecasts for each market segment to assist with long term planning. Discussion of Competitive Products in the market and new products in the delivery pipeline. Coverage of Generic...Published: March 25, 2011 | Price: $150.00 – $300.00
The Asian vaccine market is relatively small compared to its population, yet it is growing, and pharmaceutical manufacturers increasingly will look to boost sales from these emerging vaccine markets. The population of nearly 4 billion people throughout Asia accounts for more than half of the global population, yet currently it is Western markets which lead vaccine sales. This hasn't stopped companies from investing in Asian vaccine markets. The graying of the population in Asia and the growth in some regions...Published: January 15, 2005 | Price: $995.00 – $1,990.00
Despite the traditional notion that nothing therapeutic can be accomplished for the 1.5 million Americans with autism and the 2 million more throughout the world, there are pharmacologic approaches to the disease that are providing some help for patients and garnering revenues for drug companies. This Market Briefing reviews the market for drugs used in the treatment of autism and related disorers, including Antidepressants, Anti-Anxiety drugs, Anti-psychotics, Anti-convulsants, and CNS stimulants for ADHD-related symptoms, forecasting revenues through 2009 gloabally and...Published: April 1, 2008 | Price: $995.00 – $7,000.00
In one sense, the opportunity for follow-on proteins is as good as ever. Some of the biggest-selling biologics developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection or are set to lose patent protection in the US in 2007 and beyond. But there are also regulatory challenges to marketing follow-on biologics in the U.S. that companies will need to navigate to prosper. In this report, Biogenerics:...Published: August 29, 2014 | Price: $3,995.00 – $7,990.00
Biopharmaceutical and Vaccine Production Markets Biopharmaceutical and Vaccine Production Markets analyzes the entire manufacturing market for biologic drugs, including both outsourcing and costs by major maufacturers spending internally on biopharmaceutical and vaccine production. As part of its coverage, the following information is provided Market Size and Projections Vaccine Manufacturing Estimates Biologic Drug Methods Trend Analysis Types of Production Outsourcing Market Regulation of the Market Competitor Profiles This study contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other...Published: November 29, 2017 | Price: $3,600.00 – $7,200.00
Estimating Market Size, Market Share, and Market Opportunity for Biopharmaceutical Contract Manufacturing Organizations Over the past several years, an unprecedented number of blockbuster drugs have lost patent protection, and this trend is expected to continue through the foreseeable future. Yet pharmaceutical companies cannot always produce their needed pipeline in-house. This has created an ideal market environment for biopharmaceutical contracting. This report, Biopharmaceutical Contract Manufacturing Market (BCMO) Market by Type of Service, by Organization and by Region, contains the following...Published: August 2, 2022 | Price: $6,000.00 – $12,000.00
This report, Biopharmaceutical Contract Manufacturing Organization (BCMO) Market, 2022, describes and discusses the global contract manufacturing markets, specifically focusing on the production of biotech (large molecule) products including extensive coverage of the biotechnology segment of the global BCMO industry. Sales estimates are provided by segment and region, expressed in current dollars. Estimates are provided for the historic 2016 to 2021 period and forecasts are provided through 2026. Further, this report examines third party manufacturing of potential and commercialized prescription drug...Published: May 8, 2019 | Price: $3,000.00 – $6,000.00
Biopharmaceuticals are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies, and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biosimilars are not generic biologics because there can be no generic form of biologics due to the complex process of creating biologics. Biosimilar Market Trends 2019 is designed to provide a snapshot of issues and trends that are affecting the biosimilar market...Published: November 14, 2017 | Price: $3,600.00 – $7,200.00
Biosimilars: Global Market, Trends and Competitor Analysis Biosimilars: Global Market, Trends, and Competitor Analysis is a detailed analysis both of the market for biosimilars and for the market effects on pharmaceutical markets. The report provides a complete picture of the biosimilars market, including information on the world, United States, EU, Germany, France, UK, Italy Spain, rest of Europe, Russia, Japan, India, China, South Korea, Australia, Brazil, Mexico, Turkey, Iran, Canada and rest of world biosimilars market to 2022. The report...Published: February 1, 2007 | Price: $2,500.00 – $7,990.00
With over 6,160 individual data points reflecting useful market data, Kalorama's Cancer Therapeutics: The Worldwide Market, 2nd Edition is the most comprehensive and recent information available on the five key cancer therapy and treatment markets in a syndicated market research report, including the following areas: Chemotherapy, including -Subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each Hormone Therapy: -Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS...Published: March 1, 2004 | Price: $2,995.00 – $5,990.00
Cardiovascular disease includes chronic conditions such as hypertension, congestive heart failure and atherosclerosis, as well as such acute conditions as myocardial infarction and cardiac arrest. While cardiovascular disease may be diagnosed at any age, it is most prevalent in later years, particularly among sedentary individuals who are also overweight or obese. With the aging of the "Baby Boom" generation, a generation that has defined the term "couch potato" and has grown up on and maintained a diet of fast-food, the...Published: February 16, 2022 | Price: $5,000.00 – $10,000.00
Cell and Gene Therapy Funding Reached $70 Billion in 2021. How Can You Keep Up with the Activity in this Industry? A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. There are now many approved therapies with proven track records. As the tools have lowered the barriers to entry for the industry, over a thousand companies have been created or become involved. Fortunately, Kalorama Information has been tracking every significant development in...Published: December 8, 2023 | Price: $5,000.00 – $10,000.00
While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years. Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area. There are now many approved therapies with proven track records. As the technologies have lowered the barriers to entry for the industry, over 1,500 therapy or tools companies have been...Published: May 22, 2023 | Price: $5,000.00 – $10,000.00
This report, Kalorama's Cell and Gene Deals and Market Analysis, tracks the dealmaking and market opportunity in cell and gene therapy. The report includes specific details of 1000+ deals from 2022-2023. A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama's CGT deals amounted to a staggering $40 billion in 2022. Understanding the deals that have been made, who is making them, and what the specific details are is critical to...Published: April 30, 2024 | Price: $5,000.00 – $10,500.00
Authoritative market research on cell therapy, gene therapy, and RNA therapy analyzing markets by disease type Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body's immune system. Recent years have seen an increase in new therapies and the pipeline indicates this trend will continue. A large range of therapeutic areas from oncology to cardiology have seen rapidly proliferating clinical trials. Cell...Published: February 18, 2022 | Price: $6,000.00 – $12,000.00
Authoritative Information on Cell and Gene Therapy Markets Cell Therapy And Gene Therapy Markets, 2021-2031 from Kalorama Information presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market) Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions) (Cell Therapy, Gene Therapy, Total Market) Cell...Published: August 1, 2007 | Price: $1,995.00 – $3,990.00
The application of nutritional knowledge is an increasingly important part of the management and treatment of disease. Demographics and product development are expected to drive growth in the market for clinical nutrition. This Kalorama Information report - Clinical Nutrition Products: The World Market, represents the second time that Kalorama Information has taken a comprehensive look at the medical nutrition markets in three segments: Infant Nutrition Enteral Nutrition Parenteral Nutrition As part of its comprehensive coverage, this report...Published: February 1, 2009 | Price: $3,995.00 – $7,590.00
This Kalorama Information report - Clinical Nutrition - focuses on three primary segments of essential medical nutrition: Infant Nutrition: (Milk-based, Soy-based, Special Needs such as Chronic Reflux or Gastrointestinal Discomfort) Enteral Nutrition (Standard and Fiber-containing Elemental and Semi-elemental, Specialized for Chronically Ill Patients) Parenteral Nutrition For each category, the report provides revenue data and forecasts for the most important segmentations. The report includes incidence of conditions which often require enteral or parenteral feeding, birth rates, over 65 population, and overall...Published: August 1, 2005 | Price: $795.00 – $1,990.00
Neurological disease that impacts the sensory pathway can produce severe chronic pain, also known as neuropathic pain. This usually is unrelated to any peripheral tissue injury. This occurs with disorders of the central nervous system (CNS), such as stroke and multiple sclerosis, or with conditions associated with peripheral nerve damage, such as mechanical injury, diabetic neuropathy or herpes zoster infection. On form of neuropathic pain that is just now gaining recognistino is complex regional pain syndrome (CRPS), also known as...Published: February 1, 2008 | Price: $895.00 – $6,990.00
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment. Kalorama Information's Congestive Heart Failure, Major...Published: June 1, 2006 | Price: $995.00 – $5,990.00
This report focuses on the specific needs and market applications of the critical care pharmaceuticals market, the options presented by the market, the factors associated with strategic market development, and prospects for the future. The major indications for critical care are discussed as well as the range of pharmaceutical products used in the critical care environment. The strategic market characteristics of the critical care pharmaceuticals market are also discussed. The trends —- cost-containment programs, restricted formulary acceptance, clinical pharmacy, and...Published: April 1, 2005 | Price: $3,500.00 – $7,000.00
The current market for diabetes products is large and growing. Both monitoring and therapeutic products have an excellent market outlook. Diabetes markets have long had major areas of unmet need, and that has not changed during the past several decades. In fact, the number of diabetic patients, especially in the United States, will increase at an accelerating rate over the next 20 years. With the recognition of diabetes as a public health issue of increasing importance, greater pressure will be...Published: March 1, 2007 | Price: $3,500.00 – $7,990.00
The market for diabetes-related products is huge and continuing to grow. However, it is not the same market as it was just 3 years ago. New trends in care, new products (both therapeutic and diagnostic), new approaches to long-term complications, and changing public health priorities along with geographic variations are shifting the sands of opportunities in diabetes care. This comprehensive re-evaluation of the major world market for diabetes monitoring and therapeutic products provides in-depth data and analysis including: Detailed epidemiology...Published: April 1, 2005 | Price: $1,995.00 – $3,990.00
This timely overview of direct to consumer (DTC) pharmaceutical marketing examines the numerous issues surrounding DTC practices and markets, using industry and consumer publications as well as interviews with industry experts. The topics examined include: DTC marketing spending by product, DTC marketing spending by company DTC marketing spending by media channel The ROI debate on the cost-effectiveness of DTC marketing expenditures Arguments for and against DTC marketing by its proponents and critics DTC marketing regulations in the U.S. and selected...Published: February 1, 2007 | Price: $2,995.00 – $4,990.00
Fueled by the promise of needle-free mechanisms for vaccine distribution and other pharmaceutical uses, the implantable/injectable drug delivery market is growing rapidly. The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to continued growth. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products. The implantable/injectable delivery drug market is a expected to grow to over $12 billion by 2010. Kalorama’s Drug Delivery Markets. Edition...Published: March 1, 2007 | Price: $2,495.00 – $4,990.00
The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality. The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers...Published: April 1, 2007 | Price: $2,495.00 – $4,990.00
New biological treatments are being developed at a record pace, but their potential could be compromised by a significant obstacle: the delivery of these drugs into the body. Pharmaceutical delivery is now nearly as important as product. Kalorama's Drug Delivery Markets Series covers these new systems. The fourth volume of this series, Kalorama's Drug Delivery Markets, Vol. IV: Transdermal and Transmucosal Drug Delivery is a complete overview of a delivery mechanism that offers some advantages: low pain, infection risk, fewer...Published: September 1, 2009 | Price: $2,995.00 – $5,990.00
With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports...Published: July 1, 2000 | Price: $995.00 – $5,990.00
Since our last edition of this report in 2007, the oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the growing elderly population that requires products with a level of ease-of-use and cost benefit, it’s no surprise that the oral drug delivery market is a...Published: April 1, 2007 | Price: $4,995.00 – $9,990.00
Novel pharmacological and biological approaches to disease are calling for novel systems of delivering therapies. This has focused attention on the market for drug delivery systems and the pharmaceuticals that are sold along with those technologies. Kalorama's Drug Delivery Systems focuses on these technologies. This offer is for the entire 4 volumes of Kalorama's 2nd edition of its Drug Delivery Markets series, covering all major types, including: Oral Delivery Implantable/Injectable Pulmonary Transdermal/Transmucosal While oral delivery remains the most popular and...Published: November 7, 2003 | Price: $746.00 – $1,492.00
Over the past three years, Kalorama Information's analysts have studied drug delivery markets from several angles. In 2001 and 2002, we published a 5-volume series on drug delivery technology, each volume devoted to a route of administration: Volume I: Oral Drug Delivery Volume II: Injectable and Implantable Drug Delivery Volume III: Pulmonary Drug Delivery Volume IV: Transdermal and Transmucousal Drug Delivery Volume V: Advanced Drug Delivery This series segmented the market by technology and included an innovative analysis that estimated...Published: October 1, 2007 | Price: $995.00 – $1,990.00
It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision. Drug pricing is one of the key levers that determine the profitability of a drug...Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the effectiveness of PTCA. To improve on this condition, medical science created stents in an attempt to keep coronary arteries open. However, one of the early...Published: June 1, 2004 | Price: $2,995.00 – $5,990.00
Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining. In the...Published: June 1, 2007 | Price: $1,990.00 – $6,990.00
Toxicity is a crucial parameter that is measured throughout the drug development process. Toxic side-effects are one of the most common reasons drug candidates fail. Toxicity can be a factor of dose, the form in which the drug is administered, and the time of exposure before elimination. Patient responses also differ widely, depending on their age and metabolism and other products in the patient’s system may augment the effect of the drug. Just twenty years ago, toxicology was something that...